View Menu Hide Menu

Recent publications and conference presentations from VHsquared include:

PEGS Europe Protein and Antibody Engineering Summit, November 13-17 2017, Lisbon, Portugal

Gastrointestinal Stability and Tissue Penetration of V565: a Novel Orally Administered Anti-TNFα Vorabody

 

 

 

Orally delivery of a novel engineered anti-TNFα domain antibody (Vorabody) for the treatment of Intestinal Bowel Disease

 

 

 

25th United European Gastroenterology Week, Oct 28- Nov 1 2017, Barcelona, Spain

A Protease-resistant Oral Domain Antibody to TNFα Delivers High Concentrations of Active Compound in Ileal Fluid of Subjects with an Ileostomy

 

 

Oral presentation – V565, A Novel Oral Domain Antibody to TNF, Reduces Colonic Mucosal Inflammation after 7 Days Oral Dosing to Patients with Ulcerative Colitis. (Contact us here for more information.)

Oral presentation – A Novel Oral Domain Antibody to Tumour Necrosis Factor (TNF), Engineered to be Stable to Intestinal Proteases, Results in High Concentrations of Active Compound Detected in Faeces of Crohn’s Patients After Oral Dosing. (You can read the abstract, OP272 here, or contact us here for more information.)


18th International Congress of Mucosal Immunology, July 19-22 2017, Washington DC, USA

Preclinical assessment of a novel anti-TNFα Vorabody™ as an oral therapy for Crohn’s Disease

 

 


Global Conference on Pharmaceutics and Drug Delivery Systems, June 29 – July 1 2017, Valencia Spain

Oral delivery of a novel domain antibody (Vorabody™) for the treatment of Crohn’s Disease

 

 

10th Annual Proteins and Antibodies Congress, April 24-25 2017, London UK

Gastrointestinal Stability and Tissue Penetration of V565:A Novel Orally Administered Anti-TNFα Vorabody™